Treatment at the end of life in patients with advanced melanoma. A multicenter DeCOG study of 1067 patients from the prospective skin cancer registry ADORegAndrea Forschner, Carmen Loquai, Katharina C. Kähler et al.|Frontiers in Immunology|2025Cited by 4
Sex-specific survival in advanced metastatic melanoma – a DeCOG study on 2032 patients of the multicenter prospective skin cancer registry ADOREGAnna‐Sophia Leven, Selma Ugurel, Claudia Pföhler et al.|European Journal of Cancer|2025Cited by 4
Presence of brain metastasis differentially impacts long-term survival after first-line therapy in melanoma depending on BRAF mutation statusJan‐Malte Placke, Selma Ugurel, Luisa Sophie Rajcsanyi et al.|Frontiers in Immunology|2025Cited by 2
Impact of Antithrombotic Therapy on Survival Outcomes in Advanced Melanoma Patients Receiving Targeted Therapy: Insights from the Prospective Multicenter ADOReg RegistryNick Zimmermann, Christoffer Gebhardt, Julian Kött et al.|EJC Skin Cancer|2025Cited by 0
Effects of age on treatment in patients with cutaneous melanoma-A multicentre analysis from the ADOREG RegistryU. Leiter-Stöppke, U. Hillen, Selma Ugurel et al.|EJC Skin Cancer|2025Cited by 0